Tetra Therapeutics
Founded Year
2010Stage
Acquired | AcquiredTotal Raised
$58.72MAbout Tetra Therapeutics
Tetra Discovery Partners uses structure‑guided drug design to discover mechanistically allosteric inhibitors of phosphodiesterase 4 (PDE4). The company's research focuses on developing new treatments for cognitive impairment in schizophrenia, depression, Alzheimer's disease, Huntington's disease, and traumatic brain injury (TBI). On May 26, 2020, Tetra Therapeutics was acquired by Shionogi & Co., Ltd. Terms of the transaction were not disclosed.
Loading...
Loading...
Tetra Therapeutics Patents
Tetra Therapeutics has filed 7 patents.
The 3 most popular patent topics include:
- adenosine receptor antagonists
- clusters of differentiation
- g protein coupled receptors
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
4/26/2019 | 4/21/2020 | Phosphodiesterase inhibitors, Clusters of differentiation, Xanthines, Adenosine receptor antagonists, G protein coupled receptors | Grant |
Application Date | 4/26/2019 |
|---|---|
Grant Date | 4/21/2020 |
Title | |
Related Topics | Phosphodiesterase inhibitors, Clusters of differentiation, Xanthines, Adenosine receptor antagonists, G protein coupled receptors |
Status | Grant |
Latest Tetra Therapeutics News
Sep 29, 2023
28-09-2023 The US Food and Drug Administration (FDA) has granted Tetra Therapeutics, now a part of Japanese drugmaker Shionogi, Rare Pediatric Disease designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism. Zatolmilast was also awarded Orphan Drug designation by the FDA in 2018. Shionogi acquired Tetra in 2020 as part of its mission to develop medications for unmet medical needs and thereby contribute meaningfully to society. Tetra’s clinical programs, which focus on addressing cognitive function in FXS and other disorders, align strategically with Shionogi’s global vision. Shionogi is advancing the zatolmilast development program with the intent, if it is approved, to offer people living with FXS the first cognitive treatment developed specifically for this rare genetic disorder.
Tetra Therapeutics Frequently Asked Questions (FAQ)
When was Tetra Therapeutics founded?
Tetra Therapeutics was founded in 2010.
Where is Tetra Therapeutics's headquarters?
Tetra Therapeutics's headquarters is located at 2220 Wealthy Street SE, Grand Rapids.
What is Tetra Therapeutics's latest funding round?
Tetra Therapeutics's latest funding round is Acquired.
How much did Tetra Therapeutics raise?
Tetra Therapeutics raised a total of $58.72M.
Who are the investors of Tetra Therapeutics?
Investors of Tetra Therapeutics include Shionogi, National Institute of Mental Health, National Institute on Aging, Grand Angels, Dolby Family Ventures and 11 more.
Loading...
Loading...